For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| General and administrative | 650,277 | - | - | |
| Research and development | 136,432 | - | - | |
| Total operating expenses | 786,709 | - | - | |
| Operating loss | -786,709 | -633,783 | -456,524.25* | |
| Interest expense | 22,713 | 23,596 | 80,011.75* | |
| Foreign currency gain (loss) | -539 | -6,092 | 1,432* | |
| Other expense | 4,000 | - | 95,977* | |
| Taxes | -50 | -113 | -679.25* | |
| Total other income (expense) | -27,302 | -29,801 | -175,236* | |
| Net loss | -814,011 | -663,584 | -631,760.25 | |
| Basic Average Shares | 281,463,410 | 281,123,410 | 278,727,759 | |
REGENEREX PHARMA, INC. (RGPX)
REGENEREX PHARMA, INC. (RGPX)